News Category
Regentis Biomaterials strengthens its intellectual property and manufacturing capabilities for GelrinC, advancing its commercialization efforts in Eur...
VERAXA Biotech's collaboration with AI firm Ardigen aims to use artificial intelligence to optimize its oncology pipeline, potentially reducing develo...
VERAXA Biotech's collaboration with AI firm Ardigen aims to enhance its oncology pipeline by using artificial intelligence to identify optimal dual-ta...
Nanox Imaging's subsidiary enters an exclusive UK reseller agreement with Vertec Scientific, expanding access to its FDA-cleared and UKCA/CE-marked AI...
Helix BioPharma has appointed Dr. Markus Loeffler as Chief Medical Officer to lead the clinical development of L-DOS47 and LEUMUNA, marking a strategi...
Quantum BioPharma reported significant expense reductions and FDA approval for its Phase 2 trial of Lucid-MS, a potential treatment for progressive mu...
Regentis Biomaterials is simultaneously progressing its GelrinC cartilage repair implant through a pivotal U.S. trial and European commercialization, ...
Helix BioPharma's board reshuffle, with CEO Thomas Mehrling appointed as director following Janusz Grabski's resignation, aligns governance with strat...
Onco-Innovations is building the scientific foundation for its precision oncology drug ONC010, a nanoparticle-encapsulated PNKP inhibitor, through man...
Researchers at the University of Manchester discovered that a subset of immune cells, previously overlooked, plays a crucial role in orchestrating and...
Quantum BioPharma reported a 53% reduction in operating expenses and received FDA approval for its Phase 2 trial of Lucid-MS, a potential treatment fo...
Regentis Biomaterials accelerates GelrinC's path to market by simultaneously progressing US Phase III trials and European commercialization, potential...
HeartBeam reports Q2 2026 progress in its heart attack detection program and initial commercial launch, with cash runway extended into 2027.
Lantern Pharma's Q2 2026 results show significant pipeline progress and strategic moves, including the establishment of Open Medicine AI as a separate...
NeOnc Technologies' NEO100 met its primary endpoint in a Phase 2a trial for recurrent brain cancer, showing significant survival benefits and tolerabi...
Quantum BioPharma is developing Lucid-MS, a therapy aimed at inhibiting myelin degradation and preserving myelin, to address progression independent o...
GeoVax offers its MVA-based hemorrhagic fever vaccine expertise and candidates to aid the global response to the fast-growing Bundibugyo Ebola outbrea...
Nutriband CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit, underscoring the company's commitment to advancing its AVERSA abu...
Regentis Biomaterials' new Japanese patent for its organic solvent-free manufacturing process of GelrinC, coupled with a recent US grant, enhances its...
Quantum BioPharma's FDA approval to initiate Phase 2 trials for Lucid-MS, a novel neuroprotective candidate targeting myelin repair, marks a pivotal s...
PX1 Research now applies seven-stage HPLC purity verification and cGMP quality control to its US-manufactured research peptides, offering batch-specif...
NanoViricides has received approval to begin a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessibl...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in TNBC models, supporting its Phase 1/2 t...
Quantum BioPharma's IND approval for Lucid-MS enables Phase 2 testing, potentially offering a novel neuroprotective approach to MS by targeting demyel...
Tonix Pharmaceuticals' second-quarter 2026 results show a significant revenue jump driven by TONMYA, the first new fibromyalgia treatment in over 15 y...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA's $11 million in sales, signaling strong commercial uptake and pipeli...
Regentis Biomaterials is progressing its GelrinC cartilage regeneration technology through clinical trials, FDA submission preparation, European comme...
Quantum BioPharma advances its two-pronged approach to neurological health, with Lucid-MS targeting myelin repair in multiple sclerosis and unbuzzd ad...
Quantum BioPharma is progressing two initiatives for neurological health: its investigational MS therapy Lucid-MS, which has an FDA IND submission for...
VERAXA Biotech's proprietary BiTAC platform and pipeline of next-generation antibody therapeutics could attract significant partnerships and licensing...
A Spanish patient initially treated for brain cancer was found to have pork tapeworm cysts, underscoring the importance of proper food preparation and...
VERAXA Biotech's VXA-222 bispecific antibody-drug conjugate program has moved into the next development stage, supported by an expanded patent portfol...
A new liquid biopsy offers a simpler way to predict which advanced lung cancer patients will respond to immunotherapy, potentially improving treatment...
GeoVax announces completion of manufacturing, regulatory, clinical, and preclinical milestones for its GEO-MVA vaccine, positioning the program for a ...
Onco-Innovations is leveraging a multi-pronged approach combining PNKP-targeted DDR inhibition, nanoparticle delivery, and causal AI to progress its l...
Researchers at Nagoya University found that the immune protein C3, when produced within tumors, may boost the effectiveness of immunotherapy, offering...
VolitionRx's new Capture-Seq technology, detailed in a peer-reviewed paper, isolates over 99% pure tumor-derived DNA, potentially addressing a $23 bil...
Tonix Pharmaceuticals announced its participation in two major investor conferences, highlighting its commercial-stage CNS and immunology pipeline and...
VERAXA Biotech has advanced its VXA-222 bispecific antibody-drug conjugate into the next development stage and expanded its patent portfolio, solidify...
NeuroThera Labs has launched a Phase IIb clinical trial at Yale Child Study Center for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, m...
SRX Global's acquisition of a stake in Vistagen Therapeutics highlights its strategy of investing in undervalued high-conviction companies, with poten...
SRX Global's acquisition of a stake in Vistagen Therapeutics signals a strategic move to unlock shareholder value in a late-stage biopharmaceutical co...
Quantum BioPharma's pilot MS imaging study with Massachusetts General Hospital reaches halfway enrollment, showing encouraging preliminary data that c...
Biotech Labz Supply Inc has expanded its online catalog to include 11 research peptides, each supported by batch-specific certificate of analysis (COA...
Oncotelic Therapeutics will present at the OTCQB Virtual Investor Conference, highlighting its progress in cancer drug development, including a Phase ...
Tonix Pharmaceuticals received FDA feedback supporting its adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody for Lyme diseas...
Recent independent research suggesting cross-reactive immune responses from licensed Ebola vaccines underscores the potential for broad-spectrum filov...
Regentis Biomaterials' GelrinC platform offers a practical, off-the-shelf solution for cartilage repair, addressing a significant unmet need in orthop...
